This means that GLP-1 can be released in one brain region, like the hypothalamus, without necessarily affecting another, such as the amygdala
This is normal and does not indicate a problem
Food & Drug Administrations regulatory labeling for semaglutide notes two key facts
GIP-agonism has no effect on cardiac ischemia, despite stimulating hormone-sensitive lipase phosphorylation and fatty acid oxidation, supporting the cardiac safety of GIP receptor agonism (RA) for use in multi-receptor agonism
Judson, G., Babidge, P., Chen, Z., & Sansom, L
Despite strong marketing claims, BPC-157 remains an experimental molecule without robust human data